Trial · NCT07108530
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
NCT07108530, Phase 2, Recruiting, Shanxi Bethune Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study. Trials, record NCT07108530. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07108530
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
- NCT number
- NCT07108530
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Shanxi Bethune Hospital
- Conditions
- Acute Myeloid Leukemia
- Interventions
Integrated IAV/MA Chemotherapy and Allo-HSCT Protocol for Adult AML, First Induction (IAV or DAV Regimen), Consolidation Therapy Options: MA or Intermediate-Dose Cytarabine Regimen, Subsequent Treatment Plan for Transplant-Eligible Patients, Allogeneic Stem Cell Transplantation Protocol, GVHD Prophylaxis Regimen, Subsequent Consolidation Therapy for Transplant-Ineligible Patients
- First posted
- 2025-08-07
- Last updated
- 2025-08-07
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease-Free Survival (DFS) | 24 months | |
| Primary | The Complete Response (CR) rate | 24 months | The Complete Response (CR) rate refers to the proportion of patients achieving complete remission in a treatment regimen. |
| Primary | Partial Response (PR) rate | 24 months | The Partial Response (PR) rate in oncology indicates the proportion of patients experiencing a significant reduction in tumor size post-treatment. |
| Primary | No Remission (NR) | 24 months | Non-Response (NR) in medicine refers to the lack of therapeutic response, indicating no significant improvement in a patient's condition post-treatment. |
| Primary | CR with incomplete hematologic recovery (CRi) | 24 months | |
| Primary | Therapeutic efficacy | 24 months | The efficacy of the preparative regimen and anti-GVHD regimen for allogeneic stem cell transplantation in AML patients. |
| Secondary | Treatment-Related Mortality (TRM) | 24 months | |
| Secondary | Overall Survival (OS) | 24 months | |
| Secondary | Event-Free Survival (EFS) | 24 months | |
| Secondary | Therapeutic efficacy | 24 months | The therapeutic efficacy of the integrated protocol, especially for high-risk AML patients (e.g., those harboring FLT3-ITD, IDH1, TP53 mutations, complex karyotype) without the use of targeted agents. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07108530
GET https://conductscience.org/api/trials/v1/NCT07108530/registered